Experiences with the Estimand
The regulatory view

Anja Schiel, PhD, Lead methodologist/Statistician
A ‘new’ framework

Clear trial objectives should be translated into key scientific questions of interest by defining suitable estimands.

- Clear trial objective
- Key scientific question of interest
- Estimand
  (‘‘what is to be estimated’’)
Construction of an estimand

It is a multi-disciplinary undertaking and should be the subject of discussion between sponsors and regulators.
Construction of an estimand

It is a multi-disciplinary undertaking and should be the subject of discussion between sponsors and regulators.
Aligning target of estimation, method of estimation, and sensitivity analysis, for a given trial objective

In general, it is important to proceed sequentially. The trial objective should determine the choice of estimands and the estimands should determine the choice of estimators, not the reverse.

Where significant issues exist to derive a reliable estimate for a particular estimand, the trial objectives need to be reconsidered from top-down to main estimator (green arrows). The main estimator should never define the trial objective from bottom-up (red arrows).
A new framework

A common language and common understanding of this framework will help sponsors planning trials and regulators in their reviews, enhancing the interactions between these parties when discussing the suitability of designs, and the interpretation of results, to support drug licensing.
Count of Background

- Regulatory: 10.4%
- Statistics, Clinical: 4.5%
- Statistics, Regulatory: 2.3%
- Clinical: 1.0%
- Other: 77.0%